One of the hottest biopharmaceutical hedge fund firms is the latest to be raising money for a new blank-check company.
EcoR1 Capital is seeking $125 million for Panacea Acquisition Corp., a special-purpose acquisition company (SPAC) looking to do some sort of deal in the biotechnology sector, according to the prospectus.
EcoR1
